- Report
- April 2023
- 69 Pages
United Kingdom
From €4200EUR$4,750USD£3,626GBP
- Report
- August 2022
- 134 Pages
Global
From €4200EUR$4,750USD£3,626GBP
- Report
- August 2022
- 116 Pages
Global
From €4200EUR$4,750USD£3,626GBP
- Report
- November 2023
- 99 Pages
Europe
From €3050EUR$3,450USD£2,633GBP
- Report
- March 2024
- 200 Pages
Global
From €3669EUR$4,150USD£3,168GBP
- Report
- January 2024
- 200 Pages
Global
From €3669EUR$4,150USD£3,168GBP
- Report
- January 2024
- 200 Pages
Global
From €3669EUR$4,150USD£3,168GBP
- Report
- January 2021
- 245 Pages
Global
From €3183EUR$3,600USD£2,748GBP
- Report
- February 2024
- 80 Pages
From €3050EUR$3,450USD£2,633GBP
- Report
- February 2024
- 79 Pages
North America
From €3050EUR$3,450USD£2,633GBP
- Report
- February 2024
- 83 Pages
Africa, Middle East
From €3050EUR$3,450USD£2,633GBP
- Report
- February 2024
- 95 Pages
Europe
From €3050EUR$3,450USD£2,633GBP
- Report
- February 2024
- 91 Pages
Asia Pacific
From €3050EUR$3,450USD£2,633GBP
- Report
- September 2023
- 173 Pages
Global
From €3934EUR$4,450USD£3,397GBP
- Report
- June 2023
- 115 Pages
United States
From €3050EUR$3,450USD£2,633GBP
- Report
- January 2022
- 148 Pages
Global
From €3934EUR$4,450USD£3,397GBP
- Report
- May 2024
- 124 Pages
Global
From €2794EUR$3,160USD£2,412GBP
€3492EUR$3,950USD£3,015GBP
- Report
- May 2024
- 100 Pages
Global
From €2794EUR$3,160USD£2,412GBP
€3492EUR$3,950USD£3,015GBP
- Report
- May 2024
- 210 Pages
Global
From €3934EUR$4,450USD£3,397GBP
- Report
- April 2023
- 178 Pages
Global
From €4377EUR$4,950USD£3,778GBP

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness.
Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD.
Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more